Stay updated with breaking news from Evaluate Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2- metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it would present new data across its rheumatology portfolio, including RINVOQ® (upadacitinib) for...
Thirty-six abstracts underscore AbbVie's commitment to advancing research to help more people living with rheumatic diseasesAdditional analysis of...
RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...